EUVIMEDEUVIMED entdecken
Crossref

Exploring the impact of RPN1 on tumorigenesis and immune response in cancer

Pengfei Luo iD, Zhimin Li iD, Haodong He iD, Yuanbin Tang iD, Lijun Zeng iD, Lunqi Luo iD, Lianjie Ouyang iD, Meiling Wen iD, Yuehua Li iD, Yongjun Jiang iD

The FASEB Journal · 2025

DOI: 10.1096/fj.202401088r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Pengfei Luo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Central Hospital of Yongzhou, Yongzhou, Hunan, China. Hauptthemen laut MEDLINE: Neoplasms, Carcinogenesis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Natural Science Foundation of Hunan Province, Scientific Research Fund Project of Hunan Province Health, the Clinical Medical Research 4310 Program of the University of South China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ribophorin family, including RPN1, has been associated with tumor progression, but its specific role in pan‐cancer dynamics remains unclear. Using data from TCGA, GTEx, and Ualcan databases, we investigated the relationship of RPN1 with prognosis, genomic alterations, and epigenetic modifications across various cancers. Differential analysis revealed elevated RPN1 expression in multiple cancer types, indicating a potential prognostic value. Amplification was the predominant mutation type of RPN1 in pan‐cancer, with notable correlations with DNA methylation and copy number variation. Gene set variation analysis identified RPN1's involvement in cancer development, immunity, and metabolism. Additionally, RPN1 expression correlated with the tumor microenvironment, immune response factors, and response to anti‐tumor therapies. Functional validation in triple‐negative breast cancer, glioblastoma, and bladder cancer cell lines demonstrated the role of RPN1 in tumor cell proliferation and migration. Our findings highlight RPN1 as a potential biomarker for cancer diagnosis and treatment response in pan‐cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsCarcinogenesisHumansBiomarkers, TumorGene Expression Regulation, NeoplasticCell ProliferationTumor MicroenvironmentCell Line, TumorDNA MethylationDNA Copy Number VariationsPrognosisEpigenesis, GeneticCell MovementMutation

Stichwörter der Autor:innen

bioinformaticsbiomarkerpredictive factorribophorin family 1tumor microenvironment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology, The Central Hospital of Yongzhou, Yongzhou, Hunan, China.
  • Department of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

ORCID-Profile: Pengfei Luo, Zhimin Li, Haodong He, Yuanbin Tang, Lijun Zeng, Lunqi Luo, Lianjie Ouyang, Meiling Wen, Yuehua Li, Yongjun Jiang

Förderung

  • Natural Science Foundation of Hunan Province
  • Scientific Research Fund Project of Hunan Province Health
  • the Clinical Medical Research 4310 Program of the University of South China

Zitieren

APA

Luo, P., Li, Z., He, H., Tang, Y., Zeng, L., Luo, L., Ouyang, L., Wen, M., Li, Y., & Jiang, Y. (2025). Exploring the impact of RPN1 on tumorigenesis and immune response in cancer. The FASEB Journal. https://doi.org/10.1096/fj.202401088r

Vancouver

Luo P, Li Z, He H, Tang Y, Zeng L, Luo L, et al. Exploring the impact of RPN1 on tumorigenesis and immune response in cancer. The FASEB Journal. 2025. doi:10.1096/fj.202401088r

BibTeX
@article{Luo2025,
  author = {Luo, Pengfei and Li, Zhimin and He, Haodong and Tang, Yuanbin and Zeng, Lijun and Luo, Lunqi and Ouyang, Lianjie and Wen, Meiling and Li, Yuehua and Jiang, Yongjun},
  title = {Exploring the impact of RPN1 on tumorigenesis and immune response in cancer},
  journal = {The FASEB Journal},
  year = {2025},
  doi = {10.1096/fj.202401088r}
}
Kostenlos starten →